TrialJournal for immunotherapy of cancer2018

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors.

Asha Nayak-Kapoor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.